A Pharmacovigilance Study In First Episode Of Psychosis; Psychopharmacological Interventions And Safety Profiles In The Peps Project.

Related Articles

A Pharmacovigilance Study In First Episode Of Psychosis; Psychopharmacological Interventions And Safety Profiles In The Peps Project.

Int J Neuropsychopharmacol. 2015 Oct 27;

Authors: Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, Gonzáles-Pinto A, Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E, Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M, and PEPs GROUP

Abstract
BACKGROUND: The characterization of first episode of psychosis (FEP) and how they should be treated are a principal issue in actual research. Realistic, naturalistic studies are necessary to represent the entire population of FEP attended in daily practice.
METHOD: 16 participating centers from the PEPs project recruited 335 FEPs, aged 7-35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-days pharmacovigilance period.
RESULTS: The majority of FEP patients received a second generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the products specifications (87.2%). 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated to lower or higher doses of antipsychotics than the recommended ones. 8 patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (p=0.043). 5.2% of the patients were being treated with long acting injectable antipsychotics (LAIAs).12.2% of the patients received anticholinergic drugs, 12.2% antidepressants and 13.7% mood stabilizers, while almost 40% received benzodiazepines.35.52% reported at least one adverse drug reaction (ADR) during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and with antipsychotic polytherapy (85.2% vs. 45.5%, p<0.001).
CONCLUSIONS: These data indicate that overall pharmacologic prescription for treating a FEP in Spain follows the clinical practice guidelines recommendations and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, LAIAs, antipsychotic combination and the use of benzodiazepines.

PMID: 26506856 [PubMed - as supplied by publisher]

A Pharmacovigilance Study In First Episode Of Psychosis; Psychopharmacological Interventions And Safety Profiles In The Peps Project.

Related Articles

A Pharmacovigilance Study In First Episode Of Psychosis; Psychopharmacological Interventions And Safety Profiles In The Peps Project.

Int J Neuropsychopharmacol. 2015 Oct 27;

Authors: Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, Gonzáles-Pinto A, Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E, Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M, and PEPs GROUP

Abstract
BACKGROUND: The characterization of first episode of psychosis (FEP) and how they should be treated are a principal issue in actual research. Realistic, naturalistic studies are necessary to represent the entire population of FEP attended in daily practice.
METHOD: 16 participating centers from the PEPs project recruited 335 FEPs, aged 7-35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-days pharmacovigilance period.
RESULTS: The majority of FEP patients received a second generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the products specifications (87.2%). 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated to lower or higher doses of antipsychotics than the recommended ones. 8 patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (p=0.043). 5.2% of the patients were being treated with long acting injectable antipsychotics (LAIAs).12.2% of the patients received anticholinergic drugs, 12.2% antidepressants and 13.7% mood stabilizers, while almost 40% received benzodiazepines.35.52% reported at least one adverse drug reaction (ADR) during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and with antipsychotic polytherapy (85.2% vs. 45.5%, p<0.001).
CONCLUSIONS: These data indicate that overall pharmacologic prescription for treating a FEP in Spain follows the clinical practice guidelines recommendations and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, LAIAs, antipsychotic combination and the use of benzodiazepines.

PMID: 26506856 [PubMed - as supplied by publisher]

Log In